An interventional study of Penditure™ Left Atrial Appendage (LAA) Exclusion System in Left Atrial Appendage Exclusion, sponsored by Medtronic Cardiac Surgery. Active, not recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Medtronic Cardiac Surgery (part of Medtronic) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to collect post-market clinical evidence on performance and clinical outcomes of the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.
Multi center, single-arm, nonrandomized, interventional, unblinded, post-market study. Up to 150 subjects will be enrolled and implanted with the Penditure™ Left Atrial Appendage (LAA) Exclusion Clip at up to 25 sites in the United States.
Subjects will be followed at 30 days, 3 months, 12-months and annually for 36-months.
Medtronic Cardiac Surgery is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Penditure™ Left Atrial Appendage (LAA) Exclusion System
Device: Penditure™ Left Atrial Appendage (LAA) Exclusion System
Exclusion of the left atrial appendage using the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.
Rate of Successful Exclusion of the Left Atrial Appendage (LAA) From the Heart
The primary efficacy endpoint is the rate of successful exclusion of the left atrial appendage (LAA) from the heart defined as the absence of residual communication (≤ 3 mm residual contrast communication) between the left atrium (LA) and the left atrial appendage (LAA). For those successfully placed devices, exclusion will be confirmed at 3 months as demonstrated by multi-detector computed tomography (MDCT) scan.
Time frame: 3 months post procedure
Rate of Device-related Serious Adverse Cardiac Events
The primary safety endpoint is the composite rate of device-related serious adverse cardiac events at 30-days post-procedure.
Time frame: 30 days post procedure
Rate of Successful Placement of the Penditure™ Left Atrial Appendage (LAA) Exclusion System
The secondary efficacy endpoint is defined as the rate of successful placement of the Penditure™ LAA Exclusion System defined as \< 10 mm of residual stump proximal to the clip at the time of the procedure (measured by intraoperative TEE with doppler) without tissue damage requiring intervention.
Time frame: At the time of procedure
Rate of Device-related Serious Adverse Cardiac Events
The secondary safety endpoint is defined as the composite device-related serious adverse cardiac event rate at 12-months and annually through 36 months.
Time frame: At 1 year, 2 year, and 3 years post procedure
Enrollment was between February 26, 2024, and March 26, 2025. Enrollments occurred at the investigational sites that performed the Penditure implant.
| Milestone | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| Started | 198 |
| Completed | 150 |
| Not completed | 48 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Death | 1 |
| Withdrew: Physician decision | 31 |
| Withdrew: Enrollment cap = 7, exclusion met after enrollment = 4 | 11 |
The primary efficacy endpoint is the rate of successful exclusion of the left atrial appendage (LAA) from the heart defined as the absence of residual communication (≤ 3 mm residual contrast communication) between the left atrium (LA) and the left atrial appendage (LAA). For those successfully placed devices, exclusion will be confirmed at 3 months as demonstrated by multi-detector computed tomography (MDCT) scan.
| Participants | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| Rate of Successful Exclusion of the Left Atrial Appendage (LAA) From the Heart | 135 |
The primary safety endpoint is the composite rate of device-related serious adverse cardiac events at 30-days post-procedure.
| Participants | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| Rate of Device-related Serious Adverse Cardiac Events | 0 |
The secondary efficacy endpoint is defined as the rate of successful placement of the Penditure™ LAA Exclusion System defined as \< 10 mm of residual stump proximal to the clip at the time of the procedure (measured by intraoperative TEE with doppler) without tissue damage requiring intervention.
| Participants | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| Rate of Successful Placement of the Penditure™ Left Atrial Appendage (LAA) Exclusion System | 145 |
The secondary safety endpoint is defined as the composite device-related serious adverse cardiac event rate at 12-months and annually through 36 months.
Results for this outcome have not been posted.
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Penditure™ Left Atrial Appendage (LAA) Exclusion System | 5/150 (3.3%) | 59/150 (39.3%) | — |
| Event | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| Atrial fibrillationCardiac disorders | 28/150 |
| Atrial flutterCardiac disorders | 4/150 |
| Cardiogenic shockCardiac disorders | 4/150 |
| Atrioventricular block completeCardiac disorders | 3/150 |
| Cardiac tamponadeCardiac disorders | 3/150 |
| Coronary artery diseaseCardiac disorders | 3/150 |
| HaemorrhageVascular disorders | 3/150 |
| Cardiac arrestCardiac disorders | 2/150 |
| Cardiac failure congestiveCardiac disorders | 2/150 |
| Ventricular dysfunctionCardiac disorders | 2/150 |
| Age, Continuous(years) | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| Mean | 67.57 ± 9.86 |
| Sex: Female, Male(Participants) | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| Female | 38 |
| Male | 112 |
| Race (NIH/OMB)(Participants) | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 6 |
| White | 140 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(Participants) | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| United States | 150 |
| BMI(kg/m^2) | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| Mean | 30.00 ± 5.91 |
| STS Predicted Risk of Mortality (%)(Percent Predicted Risk of Mortality) | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| Mean | 1.68 ± 1.37 |
| STS not applicable, surgeon assessed risk level(Participants) | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| Low Risk | 15 |
| Intermediate Risk | 5 |
| High Risk/Extreme Risk | 0 |
| Ejection Fraction (%)(Percent of ejected blood from ventricle) | Penditure™ Left Atrial Appendage (LAA) Exclusion System |
|---|---|
| Mean | 57.46 ± 8.74 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2024 to primary completion in Aug 2025, 18 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.